Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Abdul Hamid Borghol, Elio R Bitar, Aya Hanna, Georges Naim, Elias A Rahal
Epstein-Barr Virus (EBV), a dsDNA herpesvirus, is believed to play a significant role in exacerbating and potentially triggering autoimmune and autoinflammatory maladies. Around 90% of the world is infected with the virus, which establishes latency within lymphocytes. EBV is also known to cause infectious mononucleosis, a self-limited flu-like illness, in adolescents. EBV is often reactivated and it employs several mechanisms of evading the host immune system. It has also been implicated in inducing host immune dysfunction potentially resulting in exacerbation or triggering of inflammatory processes...
April 18, 2024: Critical Reviews in Microbiology
#2
JOURNAL ARTICLE
Maria Schletzbaum, W Ryan Powell, Shivani Garg, Joseph Kramer, Brad C Astor, Andrea Gilmore-Bykovskyi, Amy J Kind, Christie M Bartels
OBJECTIVE: In systemic lupus erythematosus, poor disease outcomes occur in young adults, patients identifying as Black or Hispanic, and socioeconomically disadvantaged patients. These identities and social factors differentially shape care access and quality that contribute to lupus health disparities in the US. Thus, our objective was to measure markers of care access and quality, including rheumatology visits (longitudinal care retention) and lupus-specific serology testing, by race and ethnicity, neighborhood disadvantage, and geographic context...
April 17, 2024: Lupus
#3
JOURNAL ARTICLE
Xiaolu Huang, Fuan Lin, Hongpu Chen
BACKGROUND: Telitacicept, an innovative drug used for the treatment of systemic lupus erythematosus (SLE), can effectively control disease progression and achieve favorable outcomes. While case reports have mentioned the use of Telitacicept in lupus nephritis (LN) treatment, its safety and efficacy in treating patients with LN have not been explored. Therefore, in this study, we aimed to evaluate the safety and efficacy of Telitacicept in managing patients with LN. METHODS: In a single-center, real-world retrospective study, 30 LN patients with poor response or adverse reactions to conventional glucocorticoids at our Hospital were enrolled to receive Telitacicept...
April 13, 2024: Clinical and Experimental Nephrology
#4
Eduardo Patiño-Martinez, Shuichiro Nakabo, Kan Jiang, Carmelo Carmona-Rivera, Wanxia Li Tsai, Dillon Claybaugh, Zu-Xi Yu, Aracely Romero, Eric Bohrnsen, Benjamin Schwarz, Miguel A Solís-Barbosa, Luz P Blanco, Mohammad Naqi, Yenealem Temesgen-Oyelakim, Michael Davis, Zerai Manna, Nehal Mehta, Faiza Naz, Stephen Brooks, Stefania dell'Orso, Sarfaraz Hasni, Mariana J Kaplan
OBJECTIVE: The Krebs cycle enzyme Aconitate Decarboxylase 1 (ACOD1) mediates itaconate synthesis in myeloid cells.. Previously, we reported that administration of 4-octyl itaconate abrogated lupus phenotype in mice. Here, we explore the role of the endogenous ACOD1/itaconate pathway in the development of murine lupus as well as their relevance in premature cardiovascular damage in SLE. METHODS: We characterized Acod1 protein expression in bone marrow-derived macrophages and human monocyte-derived macrophages, following a TLR7 agonist (imiquimod, IMQ)...
February 22, 2024: medRxiv
#5
JOURNAL ARTICLE
Limin Ren, Chuchu Zhao, Yi Zhao, Huiqiong Zhou, Liyun Zhang, Youlian Wang, Lingxun Shen, Wenqiang Fan, Yang Li, Xiaomei Li, Jibo Wang, Yongjing Cheng, Jiajing Peng, Xiaozhen Zhao, Miao Shao, Ru Li
OBJECTIVE: To investigate the rates of low disease activity and clinical remission in patients with systemic lupus erythematosus (SLE) in a real-world setting, and to analyze the related factors of low disease activity and clinical remission. METHODS: One thousand patients with SLE were enrolled from 11 teaching hospitals. Demographic, clinical and laboratory data, as well as treatment regimes were collec-ted by self-completed questionnaire. The rates of low disease activity and remission were calculated based on the lupus low disease activity state (LLDAS) and definitions of remission in SLE (DORIS)...
April 18, 2024: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
#6
JOURNAL ARTICLE
Tao Wang, Dan Song, Xuejuan Li, Yu Luo, Dianqiang Yang, Xiaoyan Liu, Xiaodan Kong, Yida Xing, Shulin Bi, Yan Zhang, Tao Hu, Yunyun Zhang, Shuang Dai, Zhiqiang Shao, Dahan Chen, Jinpao Hou, Esteban Ballestar, Jianchun Cai, Feng Zheng, James Y Yang
Endosomal single-stranded RNA-sensing Toll-like receptor-7/8 (TLR7/8) plays a pivotal role in inflammation and immune responses and autoimmune diseases. However, the mechanisms underlying the initiation of the TLR7/8-mediated autoimmune signaling remain to be fully elucidated. Here, we demonstrate that miR-574-5p is aberrantly upregulated in tissues of lupus prone mice and in the plasma of lupus patients, with its expression levels correlating with the disease activity. miR-574-5p binds to and activates human hTLR8 or its murine ortholog mTlr7 to elicit a series of MyD88-dependent immune and inflammatory responses...
April 8, 2024: Cell Communication and Signaling: CCS
#7
REVIEW
Yi Zhou, Zhangxue Hu
The interleukin (IL)-17 axis is involved in many inflammatory and autoimmune diseases. Secukinumab, an IL-17 inhibitor, has been approved for psoriasis treatment. There are accumulating cases of lupus erythematosus induced by IL-17 inhibition. Lupus nephritis after IL-17 inhibition has not been reported. We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low...
May 2024: Lupus
#8
JOURNAL ARTICLE
Ying Zhu, Kexin Zhu, Xueyi Zhang, Zhijie Qian, Qingqing Guo, Xuefeng Xu, Genhong Yao, Xiaojun Tang, Dandan Wang, Huayong Zhang, Xuebing Feng, Ziyi Jin, Lingyun Sun
OBJECTIVE: To evaluate the incidence and associated factors of initial and recurrent severe infections in hospitalized patients with systemic lupus erythematosus (SLE). METHODS: SLE patients that first hospitalized between 2010 and 2021 were studied retrospectively and divided into SLE with and without baseline severe infection groups. The primary outcome was the occurrence of severe infection during follow-up. Cox regression models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for initial and recurrent severe infections...
April 2024: International Journal of Rheumatic Diseases
#9
JOURNAL ARTICLE
Xiaoting Wen, Elizabeth Ogunrinde, Zhuang Wan, Melissa Cunningham, Gary Gilkeson, Wei Jiang
OBJECTIVE: Black groups have increased prevalence and accelerated pathogenicity of systemic lupus erythematosus (SLE) compared to other ethnic/racial groups. The microbiome and systemic microbial translocation are considered contributing factors to SLE disease pathogenesis. However, racial differences in the plasma microbiome and microbial translocation in lupus remain unknown. METHODS: In the current study, we investigated plasma levels of microbial translocation (lipopolysaccharide [LPS] and zonulin) and the plasma microbiome using microbial 16S RNA sequencing of Black and White patients with SLE and Black and White healthy controls...
April 2, 2024: ACR open rheumatology
#10
JOURNAL ARTICLE
Bernadete L Liphaus, Simone C Silva, Patrícia Palmeira, Clovis A Silva, Claudia Goldenstein-Schainberg, Magda Carneiro-Sampaio
BACKGROUND: Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer (NK) cells have also been implicated. This study assessed apoptosis-related protein expressions in NK cells of patients with juvenile-onset systemic lupus erythematosus (jSLE) and relations to disease activity parameters, nephritis, and neuropsychiatric involvement...
2024: Frontiers in Immunology
#11
REVIEW
Maurizio Bruschi, Andrea Angeletti, Marco Prunotto, Pier Luigi Meroni, Gian Marco Ghiggeri, Gabriella Moroni, Renato Alberto Sinico, Franco Franceschini, Micaela Fredi, Augusto Vaglio, Andrea Cavalli, Leonardo Scapozza, Jigar J Patel, John C Tan, Ken C Lo, Lorenzo Cavagna, Andrea Petretto, Federico Pratesi, Paola Migliorini, Francesco Locatelli, Giulia Pazzola, Giampaola Pesce, Domenico Giannese, Angelo Manfredi, Giuseppe A Ramirez, Pasquale Esposito, Giuseppe Murdaca, Simone Negrini, Federica Bui, Barbara Trezzi, Giacomo Emmi, Ilaria Cavazzana, Valentina Binda, Paride Fenaroli, Isabella Pisan, Carlomaurizio Montecucco, Domenico Santoro, Francesco Scolari, Federica Mescia, Stefano Volpi, Marta Mosca, Angela Tincani, Angelo Ravelli, Corrado Murtas, Giovanni Candiano, Gianluca Caridi, Edoardo La Porta, Enrico Verrina
Deposition of autoantibodies in glomeruli is a key factor in the development of lupus nephritis (LN). For a long time, anti-dsDNA and anti-C1q antibodies were thought to be the main cause of the kidney damage. However, recent studies have shown that the list of autoantibidies that have renal tropism and deposit in the kidney in LN is increasing and the link between anti-dsDNA and renal pathology is weak due to potential confounders. Aspecific bindings of dsDNA with cationic antibodies and of anti-dsDNA with several renal antigens such as actinin, laminin, entactin, and annexinA2 raised doubts about the specific target of these antibodies in the kidney...
March 27, 2024: Autoimmunity Reviews
#12
JOURNAL ARTICLE
Yevgeniya Gartshteyn, Laura Geraldino-Pardilla, Leila Khalili, Shoiab Bukhari, Shalom Lerrer, Robert J Winchester, Anca D Askanase, Adam Mor
INTRODUCTION: T follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein (SAP) regulates TFH and TPH function by binding to the co-stimulatory signaling lymphocyte activation molecule family (SLAMF) receptors that mediate T cell - B cell interactions. SAP and SLAMF are critical for TPH-dependent B cell maturation into autoantibody-producing plasma cells that characterize SLE pathogenesis...
2024: Frontiers in Immunology
#13
Emily R Littman, Kathleen Mccabe, Shazia Beg
Breast implants, whether silicone or saline-filled, have a silicone shell and have been used for decades. Studies have shown an association between silicon with systemic lupus erythematosus, rheumatoid arthritis, progressive systemic sclerosis, and vasculitis. However, controversy and inconsistency have been pervasive in the literature with respect to the role of breast implants in the development of autoimmune diseases. A 39-year-old female with a past medical history of breast cancer and a family history of Sjogren's syndrome was referred to rheumatology for positive antinuclear antibodies (ANA) and polyarthralgia...
February 2024: Curēus
#14
JOURNAL ARTICLE
Joanna Kosałka-Węgiel, Radosław Dziedzic, Andżelika Siwiec-Koźlik, Magdalena Spałkowska, Mamert Milewski, Joanna Żuk-Kuwik, Lech Zaręba, Stanisława Bazan-Socha, Mariusz Korkosz
BACKGROUND: Lupus nephritis (LN) manifests systemic lupus erythematosus (SLE) and is characterized by various clinical and laboratory features. This study aimed to comprehensively evaluate the characteristics of LN patients according to the time of LN diagnosis: early-onset (LN diagnosed within one year from SLE diagnosis) vs. delayed-onset (LN diagnosed more than one year after SLE diagnosis). METHODS: We conducted a retrospective analysis of medical records from all SLE patients treated at the University Hospital in Kraków, Poland, from 2012 to 2022...
March 28, 2024: Rheumatology International
#15
JOURNAL ARTICLE
Irene Carrión-Barberà, Laura Triginer, Laura Tío, Carolina Pérez-García, Anna Ribes, Victoria Abad, Ana Pros, Jordi Monfort, Tarek Carlos Salman-Monte
It has been postulated that advanced glycation end products (AGEs) and their soluble receptor (sRAGE) may play a relevant role as inducers in the chronic inflammatory pathway in various conditions, among them, in immune-mediated diseases such as systemic lupus erythematosus (SLE). However, previous studies show conflicting results about their association with SLE characteristics and their usefulness as disease biomarkers. We aimed to study the association of specific serum AGEs (pentosidine, Nξ-(carboxymethyl)lysine (CML), Nξ-(carboxyethyl)lysine (CEL)), sRAGE levels and AGEs (specific serum AGEs and skin AGEs) to sRAGE ratios with various disease parameters, in order to clarify their potential as new biomarkers in SLE and to study their relationship with cardiovascular disease (CVD)...
March 7, 2024: Biomedicines
#16
JOURNAL ARTICLE
Luisa Viveiros, Ana Neves, Teresa Gouveia, David A Isenberg
OBJECTIVES: Age has a significant impact on systemic lupus erythematosus (SLE). However, data on very late-onset SLE (vlSLE) are scarce. We have compared the clinical and serological features of vlSLE patients with younger-onset patients. METHODS: We assessed the clinical and laboratory data of all patients fulfilling SLE classification criteria evaluated at a university hospital from 1978 to 2023. Patients were divided into 4 groups according to age at diagnosis: juvenile SLE (jSLE <8 years); adult SLE (aSLE 18-49 years); late SLE (lSLE 50-59 years); vlSLE (≥60 years)...
March 19, 2024: Clinical and Experimental Rheumatology
#17
JOURNAL ARTICLE
Lanlan Ji, Yan Geng, Xiaohui Zhang, Xuerong Deng, Zhibo Song, Meng Tan, Ying Tan, Chenxue Qu, Zhuoli Zhang
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B-cell hyperactivity. Telitacicept is a transmembrane activator, calcium modulator, and cyclophilin ligand interactor-Fc fusion protein, which can neutralize both B-cell lymphocyte stimulator and a proliferation-inducing ligand. Patients with active SLE who received telitacicept were prospectively followed at month 1, 3, 6, 9, and 12 after telitacicept initiation. Thirty-seven participants were involved and followed for 6...
April 2024: MedComm
#18
JOURNAL ARTICLE
Qi Wu, Ming-Xue Zhao, Xiao-Shan Huang, Chang-Song Lin, Qiang Xu
OBJECTIVE: The objective of this study is to provide a description of a group of retrospective cohort outcomes in patients with systemic lupus erythematosus (SLE) complicated with immune thrombocytopenia (ITP) receiving belimumab. METHODS: This study reports on the treatment of 10 female patients (mean age 34.3 ± 14.0 years, mean weight 58.7 ± 18.2 kg) with both SLE and ITP who received belimumab in addition to basic drug therapy. The belimumab treatment regimen consisted of a dosage of 10 mg/kg, with an initial infusion every 2 weeks for the first 3 doses, followed by an infusion every 4 weeks...
March 22, 2024: Lupus
#19
JOURNAL ARTICLE
Brendan Denvir, Philip M Carlucci, Kelly Corbitt, Jill P Buyon, H Michael Belmont, Heather T Gold, Jane E Salmon, Anca Askanase, Joan M Bathon, Laura Geraldino-Pardilla, Yousaf Ali, Ellen M Ginzler, Chaim Putterman, Caroline Gordon, Kamil E Barbour, Charles G Helmick, Hilary Parton, Peter M Izmirly
OBJECTIVE: Leveraging the Manhattan Lupus Surveillance Program (MLSP), a population-based registry of cases of systemic lupus erythematosus (SLE) and related diseases, we investigated the proportion of SLE with concomitant rheumatic diseases, including Sjögren's disease (SjD), antiphospholipid syndrome (APLS), and fibromyalgia (FM), as well as the prevalence of autoantibodies in SLE by sex and race/ethnicity. METHODS: Prevalent SLE cases fulfilled one of three sets of classification criteria...
2024: Front Epidemiol
#20
REVIEW
Aliya Botabekova, Chokan Baimukhamedov, Olena Zimba, Pankti Mehta
Rhupus, in the broad sense, refers to an overlap between rheumatoid arthritis (RA) and lupus. However, there is a paucity of data on the appropriate diagnostic/classification criteria that should be used to define rhupus. Hence, we undertook this narrative review to analyze the clinical characteristics, radiology, and treatment with a focus on diagnostic challenges and defining features of rhupus. The databases of Medline/PubMed, Scopus, and DOAJ were searched for relevant articles using the following keywords: ("Rhupus"), ("lupus" AND "erosive" AND "arthritis"), and ("lupus" AND "rheumatoid arthritis" AND "overlap")...
March 21, 2024: Rheumatology International
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
